title: [Inflammation and diabetes].
abstract: The focus of current diabetes research is the clarification of the pathogenetic relationships between subclinical inflammation, diabetes and arteriosclerosis. Even minimal disturbances in glucose tolerance are associated with a chronic, generalized inflammatory reaction that links components of the metabolic syndrome and contributes to the development of diabetic complications as well as to the development and progression of arteriosclerosis. The most important mediators and markers of this inflammation cascade are NF-kappaB, TNF-alpha, IL-6, CRP and PAI-1. For the treatment of subclinical inflammation, substances with anti-inflammatory properties such as statins or ACE inhibitors are of increasing importance.
authors.affiliation: Institut für Diabetesforschung und Med. Klinik 3, Lehrkrankenhaus München-Schwabing.
authors.forename: K
authors.initials: K
authors.lastname: Löbner
authors.forename: M
authors.initials: M
authors.lastname: Füchtenbusch
mesh_terms: D052242:Adiponectin; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000209:etiology*; D001241:Aspirin / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight; D002097:C-Reactive Protein / Q000032:analysis; D002908:Chronic Disease; D003922:Diabetes Mellitus, Type 1 / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control; D015444:Exercise; D006801:Humans; D006973:Hypertension / Q000209:etiology*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007249:Inflammation / Q000150:complications* / Q000188:drug therapy / Q000209:etiology; D018836:Inflammation Mediators; D007328:Insulin / Q000627:therapeutic use; D007333:Insulin Resistance; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood / Q000502:physiology; D024821:Metabolic Syndrome; D009765:Obesity / Q000150:complications*; D012106:Research; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use
chemical_list: D052242:Adiponectin; D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D018836:Inflammation Mediators; D007328:Insulin; D036341:Intercellular Signaling Peptides and Proteins; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D002097:C-Reactive Protein; D001241:Aspirin